Advantages and disadvantages of coronary drug-eluting stent: a 23-year journey of randomized clinical trials
Introducing drug-eluting stents (DES2) significantly reduced target vessel revascularization (TVR), TVR-myocardial infarction (MI), and definitive stent thrombosis. Cardiac death in high-risk subgroups of lesions was also significantly reduced, and all of this is out of the discussion for...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Academia.edu Journals
2024-07-01
|
| Series: | Academia Medicine |
| Online Access: | https://www.academia.edu/121774093/Advantages_and_disadvantages_of_coronary_drug_eluting_stent_a_23_year_journey_of_randomized_clinical_trials |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823859663466135552 |
|---|---|
| author | Alfredo E. Rodriguez Juan Mieres Juan M. Rokos |
| author_facet | Alfredo E. Rodriguez Juan Mieres Juan M. Rokos |
| author_sort | Alfredo E. Rodriguez |
| collection | DOAJ |
| description |
Introducing drug-eluting stents (DES2) significantly reduced target vessel revascularization (TVR), TVR-myocardial infarction (MI), and definitive stent thrombosis. Cardiac death in high-risk subgroups of lesions was also significantly reduced, and all of this is out of the discussion for the authors. However, that should be counterbalanced by the high incidence of spontaneous MI mainly due to early neo-atherosclerosis with DES. The finding of a high incidence of non-cardiac death observed in DES trials compared to coronary artery bypass grafting and optimal medical treatment is disturbing, and the reasons are unknown. Prompt action should be taken by the sponsors of the trials, scientific societies, and/or regulatory agencies to confirm or discard this intriguing observation. For now, it seems reasonable that DES2 should be indicated in all high-risk or high-complexity lesions; however, alternative strategies may be explored in all other scenarios until more information arrives. Time is running out. |
| format | Article |
| id | doaj-art-18b7ecc353c540eb93455d3eafe0ec3f |
| institution | Kabale University |
| issn | 2994-435X |
| language | English |
| publishDate | 2024-07-01 |
| publisher | Academia.edu Journals |
| record_format | Article |
| series | Academia Medicine |
| spelling | doaj-art-18b7ecc353c540eb93455d3eafe0ec3f2025-02-10T22:28:31ZengAcademia.edu JournalsAcademia Medicine2994-435X2024-07-011310.20935/AcadMed7275Advantages and disadvantages of coronary drug-eluting stent: a 23-year journey of randomized clinical trialsAlfredo E. Rodriguez0Juan Mieres1Juan M. Rokos2Cardiac Unit, Otamendi Hospital, Cardiovascular Research Center (CECI), Buenos Aires C1115AAB, Argentina.Cardiac Unit, Otamendi Hospital, Cardiovascular Research Center (CECI), Buenos Aires C1115AAB, Argentina.Cardiac Unit, Otamendi Hospital, Cardiovascular Research Center (CECI), Buenos Aires C1115AAB, Argentina. Introducing drug-eluting stents (DES2) significantly reduced target vessel revascularization (TVR), TVR-myocardial infarction (MI), and definitive stent thrombosis. Cardiac death in high-risk subgroups of lesions was also significantly reduced, and all of this is out of the discussion for the authors. However, that should be counterbalanced by the high incidence of spontaneous MI mainly due to early neo-atherosclerosis with DES. The finding of a high incidence of non-cardiac death observed in DES trials compared to coronary artery bypass grafting and optimal medical treatment is disturbing, and the reasons are unknown. Prompt action should be taken by the sponsors of the trials, scientific societies, and/or regulatory agencies to confirm or discard this intriguing observation. For now, it seems reasonable that DES2 should be indicated in all high-risk or high-complexity lesions; however, alternative strategies may be explored in all other scenarios until more information arrives. Time is running out.https://www.academia.edu/121774093/Advantages_and_disadvantages_of_coronary_drug_eluting_stent_a_23_year_journey_of_randomized_clinical_trials |
| spellingShingle | Alfredo E. Rodriguez Juan Mieres Juan M. Rokos Advantages and disadvantages of coronary drug-eluting stent: a 23-year journey of randomized clinical trials Academia Medicine |
| title | Advantages and disadvantages of coronary drug-eluting stent: a 23-year journey of randomized clinical trials |
| title_full | Advantages and disadvantages of coronary drug-eluting stent: a 23-year journey of randomized clinical trials |
| title_fullStr | Advantages and disadvantages of coronary drug-eluting stent: a 23-year journey of randomized clinical trials |
| title_full_unstemmed | Advantages and disadvantages of coronary drug-eluting stent: a 23-year journey of randomized clinical trials |
| title_short | Advantages and disadvantages of coronary drug-eluting stent: a 23-year journey of randomized clinical trials |
| title_sort | advantages and disadvantages of coronary drug eluting stent a 23 year journey of randomized clinical trials |
| url | https://www.academia.edu/121774093/Advantages_and_disadvantages_of_coronary_drug_eluting_stent_a_23_year_journey_of_randomized_clinical_trials |
| work_keys_str_mv | AT alfredoerodriguez advantagesanddisadvantagesofcoronarydrugelutingstenta23yearjourneyofrandomizedclinicaltrials AT juanmieres advantagesanddisadvantagesofcoronarydrugelutingstenta23yearjourneyofrandomizedclinicaltrials AT juanmrokos advantagesanddisadvantagesofcoronarydrugelutingstenta23yearjourneyofrandomizedclinicaltrials |